Stay updated on Nivolumab + Brentuximab Vedotin in Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab + Brentuximab Vedotin in Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab + Brentuximab Vedotin in Hodgkin Lymphoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    Screenshots show only minor UI adjustments on the page. The core study information such as title, eligibility criteria, outcomes, and locations appears unchanged.
    Difference
    0.3%
    Check dated 2025-10-27T21:06:50.000Z thumbnail image
  4. Check
    37 days ago
    Change Detected
    Summary
    Major update: operating-status notice and new version v3.2.0; old v3.1.0 reference removed.
    Difference
    3%
    Check dated 2025-10-06T08:15:24.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    Changed the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.
    Difference
    0.1%
    Check dated 2025-09-29T04:47:24.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    Patch-level version bump from v3.0.1 to v3.0.2 and removal of the Back to Top element; no substantive changes to core content, pricing, stock, or time-slot information.
    Difference
    0.2%
    Check dated 2025-09-14T22:15:19.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.
    Difference
    0.2%
    Check dated 2025-09-07T19:27:36.000Z thumbnail image
  8. Check
    72 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of a facility name and location, as well as detailed information on various medical terms and treatments related to Hodgkins lymphoma and associated proteins. Notably, the previous version's references to certain terms and agents have been removed.
    Difference
    3%
    Check dated 2025-08-31T12:34:20.000Z thumbnail image

Stay in the know with updates to Nivolumab + Brentuximab Vedotin in Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab + Brentuximab Vedotin in Hodgkin Lymphoma Clinical Trial page.